Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: Triple positive tumours are more likely lymph node positive

Breast Cancer Research and Treatment

Volumn 113, Issue 1, 2009, Pages 181-187

  Van Calster, Ben ^a   Vanden Bempt, Isabelle ^a   Drijkoningen, Maria ^a   Pochet, Nathalie ^a   Cheng, Jiqiu ^a   Van Huffel, Sabine ^a   Hendrickx, Wouter ^a   Decock, Julie ^a   Huang, Huei Jean ^a   Leunen, Karin ^a   Amant, Frederic ^a   Berteloot, Patrick ^a   Paridaens, Robert ^a   Wildiers, Hans ^a   Van Limbergen, Erik ^a   Weltens, Caroline ^a   Timmerman, Dirk ^a   Van Gorp, Toon ^a   Smeets, Ann ^a   Van Den Bogaert, Walter ^a   Vergote, Ignace ^a   Christiaens, Marie Rose ^a   Neven, Patrick ^a   more..

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Breast cancer; HER 2; Lymph node; Steroid receptors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; TUMOR VOLUME;

ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; AXILLA; BREAST NEOPLASMS; FEMALE; GENES, ERBB-2; HUMANS; LIKELIHOOD FUNCTIONS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; ODDS RATIO; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 58049213826     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-9914-7     Document Type: Article

References (51)

1. FJ Esteva GN Hortobagyi 2004 Prognostic molecular markers in early breast cancer Breast Cancer Res 6 109 118
2. T Akiyama C Sudo H Ogawara 1986 The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity Science 232 1644 1646
3. DJ Slamon GM Clark SG Wong 1987 Human breast cancer: correlation of relapse and survival with amplification of the HER-2 oncogene Science 235 177 182
4. DJ Slamon W Godolphin LA Jones 1989 Studies of the HER-2 proto-oncogene in human breast and ovarian cancer Science 244 707 712
5. S Paik R Hazan ER Fisher 1990 Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer J Clin Oncol 8 103 112
6. JS Ross JA Fletcher GP Linette 2003 The HER-2 gene and protein in breast cancer 2003: biomarker and target of therapy Rev Oncologist 8 307 325
7. Elledge RM, Allred DC (2004) Clinical aspects of estrogen and progesterone receptors. In: Harris JR, Lippman ME, Morrow M et al (eds) Diseases of the breast (ed 3). Lippincott Williams and Wilkins, Philadelphia, PA, pp 603-617
8. T Saphner DC Tormey R Gray 1996 Annual hazard rates of recurrence for breast cancer after primary therapy J Clin Oncol 14 2738 2746
9. VR Grann AB Troxel NJ Zojwalla JS Jacobson D Hershman AI Neugut 2005 Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma Cancer 103 2241 2251
10. V-J Bardou G Arpino RM Elledge 2003 Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases J Clin Oncol 21 1973 1979
11. R Zeillinger F Kury K Czerwenka 1989 HER-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer Oncogene 4 109 114
12. X Cui R Schiff G Arpino CK Osborne AV. S Lee Kato H Endoh Y Masuhiro 1995 Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase Science 270 1491 1494
13. AV Lee X Cui S Oesterreich 2001 Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer Review Clin Cancer Res 7 4429 4435 (Suppl 12)
14. G Konecny G Pauletti M Pegram 2003 Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer J Natl Cancer Inst 95 142 153
15. HJ Huang P Neven M Drijkoningen 2005 Association between tumour characteristics and HER-2 by immunohistochemistry in 1362 women with primary operable breast cancer J Clin Pathol 58 611 616
16. X Cui R Schiff G Arpino CK Osborne AV Lee 2005 Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy J Clin Oncol 23 7721 7735 (Review)
17. T Sorlie CM Perou R Tibshirani 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 10869 10874
18. T Sorlie R Tibshirani J Parker 2003 Repeated observation of breast tumor subtypes in independent gene expression data sets Proc Natl Acad Sci USA 100 8418 8423
19. C Fan DS Oh L Wessels 2006 Concordance among gene-expression-based predictors for breast cancer N Engl J Med 355 560 569
20. LA Carey CM Perou CA Livasy 2006 Race, breast cancer subtype and survival in the Carolina breast cancer study JAMA 295 2492 2502
21. B Fisher 1977 Biological and clinical considerations regarding the use of surgery and chemotherapy in the treatment of primary breast cancer Cancer 40 Suppl1 574 587
22. LK Dunnwald MA Rossing CI Li 2007 Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients Breast Cancer Res 9 R6
23. EW Elston IO Ellis 1991 Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up Histopathology 19 403 410
24. Hosmer DW, Lemeshow S (2000) Applied logistic regression (2nd ed). Wiley, New York
25. JA Sterne G Davey Smith 2001 Sifting the evidence-what's wrong with significance tests Br Med J 322 226 231
26. PM Ravdin M De Laurentiis T Vendely GM Clark 1994 Prediction of axillary lymph node status in breast cancers by prognostic indicators J Natl Cancer Inst 86 1771 1775
27. C Gajdos PI Tartter IJ Bleiweiss 1999 Lymphatic invasion, tumor size, and age are independent predictors of axillary lymph node metastases in women with T1 breast cancers Ann Surg 220 692 696
28. PH Gann SA Colilla SM Gapstur DJ Winchester DP Winchester 1999 Factors associated with axillary lymph node metastasis from breast carcinoma Cancer 86 1511 1519
29. MJ Silverstein KA Skinner TJ Lomis 2001 Predicting axillary nodal positivity in 2282 patients with breast carcinoma World J Surg 25 767 772
30. B Chua O Ung R Taylor J Boyages 2001 Frequency and predictors of axillary lymph node metastases in invasive breast cancer ANZ J Surg 71 723 728
31. G Viale S Zurrida E Maiorano 2005 Predicting the status of axillary sentinel lymph nodes in 4351 patients with invasive breast carcinoma treated in a single institution Cancer 103 492 500
32. NR Patani MV Dwek M Douek 2007 Predictors of axillary lymph node metastasis in breast cancer: a systemic review Eur J Surg Oncol 33 409 419
33. F Revillion J Bonneterre JP Peyrat 1998 ERBB2 oncogene in human breast cancer and its clinical significance Rev Eur J Cancer 34 791 808
34. JM Bartlett IO Ellis M Dowsett 2007 Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER)-negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy J Clin Oncol 25 4423 4430
35. S Taucher M Rudas RM Mader 2003 Do we need HER-2/neu testing for all patients with primary breast carcinoma? Cancer 98 2547 2553
36. AC Wolff ME Hammond JN Schwartz 2007 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 118 145
37. J Shou S Massarweh CK Osborne 2004 Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer J Natl Cancer Inst 96 926 935
38. KI Pritchard LE Shepherd FP O'Malley 2006 HER2 and responsiveness of breast cancer to adjuvant chemotherapy N Engl J Med 354 2103 2111
39. Mackey JR, Kaufman B, Clemens M et al (2006) Trastuzumab prolongs progressive-free survival in hormone-dependent and HER-2 positive metastatic breast cancer. Breast Cancer Res Treat 100 S1:S5-Abstr 3
40. CA Lange JK Richer T Shen 1998 Convergence of progesterone and epidermal growth factor signaling in breast cancer. Potentiation of mitogen-activated protein kinase pathways J Biol Chem 273 31308 31316
41. J Schneider M Pollan A Tejerina J Sanchez AR Lucas 2003 Accumulation of uPA-PAI-I complexes inside the tumour cells is associated with axillary nodal invasion in progesterone-receptor-positive early breast cancer Brit J Cancer 88 96 101
42. CJ Lockwood 2001 Regulation of plasminogeen activator inhibitor I expression by interaction of epidermal growth factor with progestin during decidualization of human endometrial stromal cells Am J Obstet Gynecol 184 798 804
43. KS Russell M-C Hung 1992 Transcriptional repression of the neu protooncogene by estrogen stimulated estrogen receptor Cancer Res 52 6624 6629
44. AK Tandon GM Clark GC Chamness A Ullrich WL McGuire 1989 HER-2/neu oncogene protein and prognosis in breast cancer J Clin Oncol 7 1120 1128
45. A Borg B Baldetorp M Ferno 1991 ERBB2 amplification in breast cancer with a high rate of proliferation. Oncogene 6 137 143
46. AH McCann PA Dervan M O'Regan 1991 Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer Cancer Res 51 3296 303
47. DC Allred GM Clark AK Tandon 1992 HER-2 in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma J Clin Oncol 10 599 605
48. RR Love NB Duc TC Havighurst 2003 HER-2 overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer J Clin Oncol 21 453 457
49. G Peiro E Adrover FI Aranda 2007 Prognostic implication of HER-2 status in steroid receptor positive, lymph node negative breast carcinoma Am J Clin Path 127 780 786
50. LH Saal K Holm M Maurer 2005 PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65 2554 2559
51. WD Foulkes JS Brunet IM Stefansson 2004 The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular- proliferation+) phenotype of BRCA1-related breast cancer Cancer Res 64 830 835